Literature DB >> 2832935

Unprocessed bran and intermittent thiazide therapy in prevention of recurrent urinary calcium stones.

M Ala-Opas1, I Elomaa, L Porkka, O Alfthan.   

Abstract

Both urinary calcium excretion and renal stone episodes are increased during the summer in Finland. Since thiazide and unprocessed bran are known to decrease urinary calcium excretion, we treated 73 patients with recurrent urinary stone formation by giving them unprocessed bran and intermittent thiazide. Of the patients, 32 had absorptive hypercalciuria and 41 had normal urinary calcium values. All patients were on a low-calcium and low-oxalate diet and took 40 g bran daily. Fourteen of the hypercalciuric and 14 of the normocalciuric patients were randomly allocated to use hydrochlorothiazide 50 mg b.i.d. from May to September. Reduction of stone formation was seen in all groups. The combination of thiazide + bran was superior to the bran on its own in inhibition of stone formation. Only 3/11 (27%) stones passed through during the summer in the thiazide + bran group as compared with the 11/17 (65%) in the bran group.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2832935     DOI: 10.3109/00365598709180789

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  7 in total

Review 1.  Prospective therapeutic studies in nephrolithiasis.

Authors:  D K Ackermann
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 2.  Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?

Authors:  Hans-Göran Tiselius
Journal:  Urolithiasis       Date:  2015-11-27       Impact factor: 3.436

Review 3.  Intestinal transport of an obdurate anion: oxalate.

Authors:  Marguerite Hatch; Robert W Freel
Journal:  Urol Res       Date:  2004-11-25

4.  Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease.

Authors:  Ryan S Hsi; Phyllis L Yan; Joseph J Crivelli; David S Goldfarb; Vahakn Shahinian; John M Hollingsworth
Journal:  Urology       Date:  2022-05-08       Impact factor: 2.633

5.  Annual Incidence of Nephrolithiasis among Children and Adults in South Carolina from 1997 to 2012.

Authors:  Gregory E Tasian; Michelle E Ross; Lihai Song; David J Sas; Ron Keren; Michelle R Denburg; David I Chu; Lawrence Copelovitch; Christopher S Saigal; Susan L Furth
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-14       Impact factor: 8.237

Review 6.  Pharmacological interventions for preventing complications in idiopathic hypercalciuria.

Authors:  Joaquin Escribano; Albert Balaguer; Filomena Pagone; Albert Feliu; Marta Roqué I Figuls
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 7.  Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.

Authors:  Giovanni Gambaro; Emanuele Croppi; Fredric Coe; James Lingeman; Orson Moe; Elen Worcester; Noor Buchholz; David Bushinsky; Gary C Curhan; Pietro Manuel Ferraro; Daniel Fuster; David S Goldfarb; Ita Pfeferman Heilberg; Bernard Hess; John Lieske; Martino Marangella; Dawn Milliner; Glen M Preminger; Jose' Manuel Reis Santos; Khashayar Sakhaee; Kemal Sarica; Roswitha Siener; Pasquale Strazzullo; James C Williams
Journal:  J Nephrol       Date:  2016-07-25       Impact factor: 3.902

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.